LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

Search

Fate Therapeutics Inc

Deschisă

SectorSănătate

1.02 -6.42

Rezumat

Modificarea prețului

24h

Curent

Minim

1

Maxim

1.1

Indicatori cheie

By Trading Economics

Venit

-4.5M

-52M

Vânzări

-1.2M

1.9M

EPS

-0.44

Marjă de profit

-2,803.925

Angajați

181

EBITDA

10M

-42M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+476.64% upside

Dividende

By Dow Jones

Următoarele câștiguri

15 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

33M

150M

Deschiderea anterioară

7.44

Închiderea anterioară

1.02

Sentimentul știrilor

By Acuity

25%

75%

58 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 mai 2025, 22:34 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

12 mai 2025, 23:46 UTC

Market Talk

Nikkei Likely to Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

12 mai 2025, 23:34 UTC

Market Talk

Trade Deal Lowers US Recession Risks to 35% -- Market Talk

12 mai 2025, 23:21 UTC

Market Talk

US-China Trade Deal Still Risks Stagflation; Supply Chain Disruption -- Market Talk

12 mai 2025, 22:54 UTC

Market Talk

Australian Treasurer Warns Uncertainty Will Still Dominate Markets -- Market Talk

12 mai 2025, 22:43 UTC

Câștiguri

Telefonica Brasil 1Q EPS BRL0.65 >VIV

12 mai 2025, 22:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 22:08 UTC

Achiziții, Fuziuni, Preluări

Ampol Expects Replacement-Cost Ebitda Uplift by Run Rate at End-2025 of Around A$30 Million/Year

12 mai 2025, 22:08 UTC

Achiziții, Fuziuni, Preluări

Ampol Expects Pretax Proceeds of Around A$65 Million From Transactions

12 mai 2025, 22:07 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell Australia Retail Electricity Business for Nominal Sum

12 mai 2025, 22:07 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell Australia Retail Electricity Business to AGL

12 mai 2025, 22:06 UTC

Achiziții, Fuziuni, Preluări

Meridian to Take on Flick, Z Energy Branded Electricity Customers

12 mai 2025, 22:06 UTC

Achiziții, Fuziuni, Preluări

Meridian Energy to Buy Business From Ampol for NZ$70 Million

12 mai 2025, 22:05 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell New Zealand Electricity Retailing Businesses to Meridian Energy

12 mai 2025, 22:04 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mai 2025, 21:15 UTC

Top știri

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- 2nd update -- WSJ

12 mai 2025, 21:01 UTC

Câștiguri

Constellation Software 1Q Rev $2.65B >CSU.T

12 mai 2025, 21:01 UTC

Câștiguri

Constellation Software 1Q Net $115M >CSU.T

12 mai 2025, 21:01 UTC

Câștiguri

Constellation Software 1Q EPS $5.44 >CSU.T

12 mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12 mai 2025, 20:50 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

12 mai 2025, 20:44 UTC

Top știri

Trade Thaw Sparks Stock Rally, Leaves Wall Street Cautious -- WSJ

12 mai 2025, 20:31 UTC

Top știri

How to Think About the Stock Market When Earnings Guidance Becomes Meaningless -- Heard on the Street -- UPDATED -- WSJ

12 mai 2025, 20:24 UTC

Câștiguri

Energy Vault Holdings: Encouraging News on China/U.S. Tariff Pause, Pending Final Positive Resolution and Timing >NRGV

12 mai 2025, 20:24 UTC

Câștiguri

Energy Vault Holdings: No Change to Current Guidance, With Potential Rev Upside on Accelerated U.S. Battery Deliveries in 2025 >NRGV

12 mai 2025, 20:24 UTC

Top știri

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- WSJ

12 mai 2025, 20:22 UTC

Achiziții, Fuziuni, Preluări

Spirit AeroSystems Holdings: IRS Rules That Sale to Boeing Will Qualify as a Reorganization Under Section 368(a)(1)(B)

12 mai 2025, 20:15 UTC

Câștiguri

Rigetti Computing Reports Earnings. How the Company Takes a Different Approach to Quantum. -- Barrons.com

12 mai 2025, 20:10 UTC

Câștiguri

Blink Charging 1Q Rev $20.8M >BLNK

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

476.64% sus

Prognoză pe 12 luni

Medie 6.17 USD  476.64%

Maxim 12 USD

Minim 2.5 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

12 ratings

4

Cumpărare

8

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.9101 / 1.14Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

58 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.